CN106890368A - For the ureter bracket and preparation method of tumour targeted therapy - Google Patents
For the ureter bracket and preparation method of tumour targeted therapy Download PDFInfo
- Publication number
- CN106890368A CN106890368A CN201510957430.7A CN201510957430A CN106890368A CN 106890368 A CN106890368 A CN 106890368A CN 201510957430 A CN201510957430 A CN 201510957430A CN 106890368 A CN106890368 A CN 106890368A
- Authority
- CN
- China
- Prior art keywords
- ureter bracket
- solution
- admh
- polymer
- targeted therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/84—Drainage tubes; Aspiration tips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/16—Materials with shape-memory or superelastic properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M2025/0059—Catheters; Hollow probes characterised by structural features having means for preventing the catheter, sheath or lumens from collapsing due to outer forces, e.g. compressing forces, or caused by twisting or kinking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of ureter bracket and preparation method for tumour targeted therapy.The ureter bracket includes：One layer of biodegradable elastomers coating containing antineoplastic is coated on ureter bracket surface.It is prepared, including：(1) ADMh is dissolved in dimethyl sulfoxide (DMSO) and obtains ADMh solution；PLA-polycaprolactone co-polymer is dissolved in tetrahydrofuran and obtains polymer solution；Then ADMh solution is added dropwise in polymer solution, is uniformly dissolved, slow releasing pharmaceutical solution is obtained；(2) ureter bracket is immersed in slow releasing pharmaceutical solution and is quickly removed, dried in an oven；(3) rami ureterici of drying is placed on vacuum drying, is obtained final product.The elastomer coating ureter bracket of the carrying antineoplastic prepared by the method for the present invention, good with ureter bracket bonding force, coating uniform is smooth.While coating stent of medicine completes drainage support, sustained release antineoplastic meets various demands of clinical treatment.
Description
Technical field
Technical field of medical instruments the invention belongs to be used to treat tumor of ureter disease, it is more particularly to a kind of fixed for tumour
To the ureter bracket and preparation method for the treatment of.
Background technology
With the development of aging population society and needle holder being applied to surgery Minimally, ureter has turned into clinical and nursing in urinary system disease
Conventional indispensable consumption equipment in disease.Ureter bracket is mainly used in disease in the urological system postoperative drainage urine and ureter wall
Repairing defect, is Urology Surgery interior drainage method the most frequently used at present.In recent years, the tumor of ureter incidence of disease increased increasingly,
Trigger the diseases such as ureteral calculi, infraction, blood urine.
At present, clinically for tumor of ureter treatment more be present in surgery excision, be aided with chemotherapy.Classic chemotherapy mode is
After antineoplastic is administered by all means, reaches certain blood concentration and be distributed in whole body and produce therapeutic action.This
The drawbacks of kind therapeutic modality has body poor selectivity, mass lesions normal structure, therapeutic effect is not good.But orientation is planted
Enter, local treatment can reduce tissue damage scope, more preferable oncotherapy effect is reached with relatively low drug concentration.
PLA, polycaprolactone and its copolymer are widely used in bracket for eluting medicament as good pharmaceutical carrier.With reference to
The polymer coating of medicine is carried into blood vessel, is eluted with the degraded of polymer, or with diffusion way directed local
Play a role, achieve good effect.In recent years, the medication coat ureter such as taxol, Ciprofloxacin, rapamycin
Support has also obtained certain research.
The content of the invention
It is an object of the invention to overcome the deficiencies in the prior art, there is provided a kind of ureter bracket for tumour targeted therapy and
Preparation method.The elastomer coating ureter bracket of the carrying antineoplastic prepared by the method for the present invention, with ureter
Support bonding force is good, and coating uniform is smooth.While coating stent of medicine completes drainage support, sustained release antineoplastic
Thing, meets various demands of clinical treatment.
The purpose of the present invention is achieved through the following technical solutions：
The first object of the present invention is to provide a kind of ureter bracket for tumour targeted therapy, including：In rami ureterici
Frame surface coats one layer of biodegradable elastomers coating containing antineoplastic.
Described antineoplastic is ADMh.
Described biodegradable elastomers are PLA-polycaprolactone co-polymer PLCL.
In described PLA-polycaprolactone co-polymer PLCL, in terms of molal quantity, lactic acid units (L-LA) account for 80%-20%,
Caprolactone units (ε-CL) account for 20%-80%.
The thickness of the described biodegradable elastomers coating containing antineoplastic is 15-40 μm.
Preferably, 30 μm of the thickness of the biodegradable elastomers coating containing antineoplastic.
The second object of the present invention is the preparation method for providing a kind of ureter bracket for tumour targeted therapy, including：
(1) slow releasing pharmaceutical solution is prepared：ADMh is dissolved in dimethyl sulfoxide (DMSO) and obtains ADMh solution；By poly- breast
Acid-polycaprolactone co-polymer is dissolved in tetrahydrofuran and obtains polymer solution；Then ADMh solution is added dropwise over polymer molten
In liquid, it is uniformly dissolved, slow releasing pharmaceutical solution is obtained；
(2) ureter bracket is immersed in the slow releasing pharmaceutical solution of step (1) preparation and is taken out after 15s, in 45 DEG C of baking ovens
Dry 72h；
(3) rami ureterici that step (2) is dried is placed on vacuum drying chamber and dries 72h, obtained final product.
ADMh and the mass volume ratio of dimethyl sulfoxide (DMSO) in the step (1) are 2-4g：100ml.
PLA-polycaprolactone co-polymer and the mass volume ratio of tetrahydrofuran in the step (1) are 15g：400ml.
In the slow releasing pharmaceutical solution of the step (1), the content of ADMh is 0.4-0.8g/100ml；PLA-gather oneself
The content of lactone copolymers is 3g/100ml.
The biodegradable elastomers that the present invention is used are the different moles of PLA-polycaprolactone co-polymers of composition.PLA-
Polycaprolactone co-polymer biocompatibility is good, and controllable of degrading, is good pharmaceutical carrier.By regulating and controlling in lactic acid and oneself
The ratio of ester regulates and controls the degradation rate of polymer, so that regulating medicine release behavior, prepares with different pharmaceutical deenergized period
Ureter bracket, meets the different demands of clinical treatment.
Compared with prior art, the positive effect of the present invention is as follows：
While the ureter bracket that the present invention is provided, its coating and rack body complete drainage and supporting role, by biology
The sustained release of the Degradation Control antineoplastic of degradable polymer, suppresses tumor cell proliferation, and then permanently effective killing
Tumour cell, improves therapeutic effect.The elastomer coating ureter of the carrying antineoplastic prepared by the method for the present invention
Support, good with ureter bracket bonding force, coating uniform is smooth.
Specific embodiment
With reference to specific embodiment, the present invention is expanded on further.It should be understood that these embodiments are merely to illustrate the present invention
Rather than limitation the scope of the present invention.In addition, it is to be understood that after the content for having read instruction of the present invention, art technology
Personnel can make various changes or modifications to the present invention, and these equivalent form of values equally fall within the application appended claims and limited
Fixed scope.
Embodiment 1
(1) slow releasing pharmaceutical solution is prepared：
0.2g ADMhs are dissolved in 10ml dimethyl sulfoxide (DMSO)s and obtain ADMh solution；By 1.5g PLAs-polycaprolactone
(LA% is that 80%, CL is 20%) to be dissolved in 40ml tetrahydrofurans to obtain polymer solution to copolymer；Then by 10ml hydrochloric acid
Doxorubicin solution is added dropwise in 40ml polymer solutions, is uniformly dissolved, and slow releasing pharmaceutical solution is obtained；The slow releasing pharmaceutical is molten
In liquid, the content of ADMh is 0.4g/100ml, and the content of PLA-polycaprolactone co-polymer is 3g/100ml；
(2) ureter bracket is cleaned by ultrasonic 20min, is then immersed in the slow releasing pharmaceutical solution of step (1) preparation
Taken out after 15s, 72h is dried in 45 DEG C of baking ovens；
(3) rami ureterici that step (2) is dried is placed on vacuum drying chamber and dries 72h, prepared low drugloading rate PLA-
Polycaprolactone coating ureter bracket.
Embodiment 2
(1) slow releasing pharmaceutical solution is prepared：
0.4g ADMhs are dissolved in 10ml dimethyl sulfoxide (DMSO)s and obtain ADMh solution；By 1.5g PLAs-polycaprolactone
(LA% is that 80%, CL is 20%) to be dissolved in 40ml tetrahydrofurans to obtain polymer solution to copolymer；Then by 10ml hydrochloric acid
Doxorubicin solution is added dropwise in 40ml polymer solutions, is uniformly dissolved, and slow releasing pharmaceutical solution is obtained；The slow releasing pharmaceutical is molten
In liquid, the content of ADMh is 0.8g/100ml, and the content of PLA-polycaprolactone co-polymer is 3g/100ml；
(2) ureter bracket is cleaned by ultrasonic 20min, is then immersed in the slow releasing pharmaceutical solution of step (1) preparation
Taken out after 15s, 72h is dried in 45 DEG C of baking ovens；
(3) rami ureterici that step (2) is dried is placed on vacuum drying chamber and dries 72h, prepared high drug load PLA-
Polycaprolactone coating ureter bracket.
Embodiment 3
(1) slow releasing pharmaceutical solution is prepared：
0.2g ADMhs are dissolved in 10ml dimethyl sulfoxide (DMSO)s and obtain ADMh solution；By 1.5g PLAs-polycaprolactone
(LA% is that 50%, CL is 50%) to be dissolved in 40ml tetrahydrofurans to obtain polymer solution to copolymer；Then by 10ml hydrochloric acid
Doxorubicin solution is added dropwise in 40ml polymer solutions, is uniformly dissolved, and slow releasing pharmaceutical solution is obtained；The slow releasing pharmaceutical is molten
In liquid, the content of ADMh is 0.4g/100ml, and the content of PLA-polycaprolactone co-polymer is 3g/100ml；
(2) ureter bracket is cleaned by ultrasonic 20min, is then immersed in the slow releasing pharmaceutical solution of step (1) preparation
Taken out after 15s, 72h is dried in 45 DEG C of baking ovens；
(3) rami ureterici that step (2) is dried is placed on vacuum drying chamber and dries 72h, prepared low drugloading rate PLA-
Polycaprolactone coating ureter bracket.
Embodiment 4
(1) slow releasing pharmaceutical solution is prepared：
0.4g ADMhs are dissolved in 10ml dimethyl sulfoxide (DMSO)s and obtain ADMh solution；By 1.5g PLAs-polycaprolactone
(LA% is that 50%, CL is 50%) to be dissolved in 40ml tetrahydrofurans to obtain polymer solution to copolymer；Then by 10ml hydrochloric acid
Doxorubicin solution is added dropwise in 40ml polymer solutions, is uniformly dissolved, and slow releasing pharmaceutical solution is obtained；The slow releasing pharmaceutical is molten
In liquid, the content of ADMh is 0.8g/100ml, and the content of PLA-polycaprolactone co-polymer is 3g/100ml；
(2) ureter bracket is cleaned by ultrasonic 20min, is then immersed in the slow releasing pharmaceutical solution of step (1) preparation
Taken out after 15s, 72h is dried in 45 DEG C of baking ovens；
(3) rami ureterici that step (2) is dried is placed on vacuum drying chamber and dries 72h, prepared high drug load PLA-
Polycaprolactone) coating ureter bracket.
Embodiment 5
(1) slow releasing pharmaceutical solution is prepared：
0.2g ADMhs are dissolved in 10ml dimethyl sulfoxide (DMSO)s and obtain ADMh solution；By 1.5g PLAs-polycaprolactone
(LA% is that 20%, CL is 80%) to be dissolved in 40ml tetrahydrofurans to obtain polymer solution to copolymer；Then by 10ml hydrochloric acid
Doxorubicin solution is added dropwise in 40ml polymer solutions, is uniformly dissolved, and slow releasing pharmaceutical solution is obtained；The slow releasing pharmaceutical is molten
In liquid, the content of ADMh is 0.4g/100ml, and the content of PLA-polycaprolactone co-polymer is 3g/100ml；
(2) ureter bracket is cleaned by ultrasonic 20min, is then immersed in the slow releasing pharmaceutical solution of step (1) preparation
Taken out after 15s, 72h is dried in 45 DEG C of baking ovens；
(3) rami ureterici that step (2) is dried is placed on vacuum drying chamber and dries 72h, prepared low drugloading rate PLA-
Polycaprolactone coating ureter bracket.
Embodiment 6
(1) slow releasing pharmaceutical solution is prepared：
0.4g ADMhs are dissolved in 10ml dimethyl sulfoxide (DMSO)s and obtain ADMh solution；By 1.5g PLAs-polycaprolactone
(LA% is that 20%, CL is 80%) to be dissolved in 40ml tetrahydrofurans to obtain polymer solution to copolymer；Then by 10ml hydrochloric acid
Doxorubicin solution is added dropwise in 40ml polymer solutions, is uniformly dissolved, and slow releasing pharmaceutical solution is obtained；The slow releasing pharmaceutical is molten
In liquid, the content of ADMh is 0.8g/100ml, and the content of PLA-polycaprolactone co-polymer is 3g/100ml；
(2) ureter bracket is cleaned by ultrasonic 20min, is then immersed in the slow releasing pharmaceutical solution of step (1) preparation
Taken out after 15s, 72h is dried in 45 DEG C of baking ovens；
(3) rami ureterici that step (2) is dried is placed on vacuum drying chamber and dries 72h, prepared high drug load PLA-
Polycaprolactone coating ureter bracket.
Drug-carried coat ureter bracket drug release explanation obtained in above-described embodiment 1-6：
Drug-carried coat ureter bracket drugloading rate is in 100-400mg/ roots.Drug-carried coat ureter bracket is inserted into simulation artificial urine
Liquid, pH=6.20,37 DEG C of simulation degradeds.Pharmaceutical polymer coating degradation cycle 2-3 month, the rate of release of ADMh
Change with the degraded of coated polymeric, add up release 40%-60%.
General principle of the invention, principal character and advantages of the present invention has been shown and described above.The technology people of the industry
Member simply illustrates this hair it should be appreciated that the present invention is not limited to the above embodiments described in above-described embodiment and specification
Bright principle, various changes and modifications of the present invention are possible without departing from the spirit and scope of the present invention, these changes
Be all fall within the protetion scope of the claimed invention with improvement.The claimed scope of the invention is by appending claims and its waits
Jljl is defined.
Claims (9)
1. a kind of ureter bracket for tumour targeted therapy, including：One layer is coated containing anti-swollen on ureter bracket surface
The biodegradable elastomers coating of tumor medicine.
2. a kind of ureter bracket for tumour targeted therapy according to claim 1, it is characterised in that：Described
Antineoplastic is ADMh.
3. a kind of ureter bracket for tumour targeted therapy according to claim 1, it is characterised in that：Described
Biodegradable elastomers are PLA-polycaprolactone co-polymer PLCL.
4. a kind of ureter bracket for tumour targeted therapy according to claim 3, it is characterised in that：Described
In PLA-polycaprolactone co-polymer PLCL, in terms of molal quantity, lactic acid units account for 80%-20%, and caprolactone units are accounted for
20%-80%.
5. a kind of ureter bracket for tumour targeted therapy according to claim 1, it is characterised in that：Described
The thickness of the biodegradable elastomers coating containing antineoplastic is 15-40 μm.
6. a kind of ureter bracket for tumour targeted therapy according to claim 5, it is characterised in that：Described
30 μm of the thickness of the biodegradable elastomers coating containing antineoplastic.
7. the preparation method of a kind of ureter bracket for tumour targeted therapy, including：
(1) slow releasing pharmaceutical solution is prepared：ADMh is dissolved in dimethyl sulfoxide (DMSO) and obtains ADMh solution；By poly- breast
Acid-polycaprolactone co-polymer is dissolved in tetrahydrofuran and obtains polymer solution；Then ADMh solution is added dropwise over polymer molten
In liquid, it is uniformly dissolved, slow releasing pharmaceutical solution is obtained；
(2) ureter bracket is immersed in the slow releasing pharmaceutical solution of step (1) preparation and is taken out after 15s, in 45 DEG C of baking ovens
Dry 72h；
(3) rami ureterici that step (2) is dried is placed on vacuum drying chamber and dries 72h, obtained final product.
8. a kind of preparation method of ureter bracket for tumour targeted therapy according to claim 7, its feature exists
In：ADMh and the mass volume ratio of dimethyl sulfoxide (DMSO) in the step (1) are 2-4g：100ml；The poly- breast
Acid-polycaprolactone co-polymer is 15g with the mass volume ratio of tetrahydrofuran：400ml.
9. a kind of preparation method of ureter bracket for tumour targeted therapy according to claim 7, its feature exists
In：In the slow releasing pharmaceutical solution of the step (1), the content of ADMh is 0.4-0.8g/100ml；PLA-gather oneself
The content of lactone copolymers is 3g/100ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510957430.7A CN106890368A (en) | 2015-12-18 | 2015-12-18 | For the ureter bracket and preparation method of tumour targeted therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510957430.7A CN106890368A (en) | 2015-12-18 | 2015-12-18 | For the ureter bracket and preparation method of tumour targeted therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106890368A true CN106890368A (en) | 2017-06-27 |
Family
ID=59189600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510957430.7A Pending CN106890368A (en) | 2015-12-18 | 2015-12-18 | For the ureter bracket and preparation method of tumour targeted therapy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106890368A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110584848A (en) * | 2019-08-31 | 2019-12-20 | 中山市普利斯微创介入医械有限公司 | Resistance to compression ureter support |
| CN112957537A (en) * | 2021-02-07 | 2021-06-15 | 西南交通大学 | Preparation method of drug-loaded sustained-release stent, product and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101234201A (en) * | 2008-01-24 | 2008-08-06 | 上海交通大学 | High molecule impregnation implantation sustained-release drug delivering system and preparation thereof |
| CN101257860A (en) * | 2005-04-05 | 2008-09-03 | 万能医药公司 | Degradable implantable medical devices |
| CN101862478A (en) * | 2010-06-12 | 2010-10-20 | 上海交通大学医学院附属新华医院 | Preparation method of bracket with drug temperature-sensitive controlled-release function |
| CN101862477A (en) * | 2010-06-12 | 2010-10-20 | 上海交通大学医学院附属新华医院 | Bracket with drug temperature-sensitive controlled-release function and application thereof |
| CN102038564A (en) * | 2009-10-14 | 2011-05-04 | 周星 | Supporting frame capable of being taken out |
| CN102319453A (en) * | 2011-08-17 | 2012-01-18 | 上海交通大学医学院附属新华医院 | Drug-loaded stent with ultrasonic intelligent controlled release |
| CN105169496A (en) * | 2015-09-30 | 2015-12-23 | 苏州纳晶医药技术有限公司 | Biodegradable stent composite |
-
2015
- 2015-12-18 CN CN201510957430.7A patent/CN106890368A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101257860A (en) * | 2005-04-05 | 2008-09-03 | 万能医药公司 | Degradable implantable medical devices |
| CN101234201A (en) * | 2008-01-24 | 2008-08-06 | 上海交通大学 | High molecule impregnation implantation sustained-release drug delivering system and preparation thereof |
| CN102038564A (en) * | 2009-10-14 | 2011-05-04 | 周星 | Supporting frame capable of being taken out |
| CN101862478A (en) * | 2010-06-12 | 2010-10-20 | 上海交通大学医学院附属新华医院 | Preparation method of bracket with drug temperature-sensitive controlled-release function |
| CN101862477A (en) * | 2010-06-12 | 2010-10-20 | 上海交通大学医学院附属新华医院 | Bracket with drug temperature-sensitive controlled-release function and application thereof |
| CN102319453A (en) * | 2011-08-17 | 2012-01-18 | 上海交通大学医学院附属新华医院 | Drug-loaded stent with ultrasonic intelligent controlled release |
| CN105169496A (en) * | 2015-09-30 | 2015-12-23 | 苏州纳晶医药技术有限公司 | Biodegradable stent composite |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110584848A (en) * | 2019-08-31 | 2019-12-20 | 中山市普利斯微创介入医械有限公司 | Resistance to compression ureter support |
| CN112957537A (en) * | 2021-02-07 | 2021-06-15 | 西南交通大学 | Preparation method of drug-loaded sustained-release stent, product and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dennis et al. | Suture materials—Current and emerging trends | |
| Liu et al. | 3D printed hydrogel/PCL core/shell fiber scaffolds with NIR-triggered drug release for cancer therapy and wound healing | |
| Ha et al. | Therapeutic effect of decellularized extracellular matrix-based hydrogel for radiation esophagitis by 3D printed esophageal stent | |
| CN104623740B (en) | A kind of medicinal balloon and preparation method thereof | |
| CN1649551B (en) | Drug-delivery endovascular stent and method for treating restenosis | |
| Ma et al. | Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies | |
| AU2014249723B2 (en) | Multi-layer biodegradable device having adjustable drug release profile | |
| CN104884545B (en) | Polymer coating compositions and coated products | |
| CN101234217B (en) | Functional targeting therapeutic degradable biological bracket and use thereof | |
| Elsner et al. | Highly porous drug-eluting structures: From wound dressings to stents and scaffolds for tissue regeneration | |
| Tseng et al. | Nanofibers used for the delivery of analgesics | |
| CN103025362A (en) | Coating of endoprostheses with a coating consisting of a tight mesh of polymer fibres | |
| CN105833358B (en) | Intracranial drug eluting stent system and preparation method thereof | |
| CN204050424U (en) | A kind of medicinal balloon | |
| JP2014531933A (en) | Intervention medical device and manufacturing method thereof | |
| Guo et al. | Biomimetic and immunomodulatory baicalin-loaded graphene oxide-demineralized bone matrix scaffold for in vivo bone regeneration | |
| CN104984412A (en) | Preparation method for paclitaxel coating on surface of drug balloon | |
| CN100435756C (en) | Arsenic trioxide control release elution stent | |
| JP2014530058A (en) | Intervention medical device and manufacturing method thereof | |
| Yang et al. | Double-modified bacterial cellulose/soy protein isolate composites by laser hole forming and selective oxidation used for urethral repair | |
| Sanchez-Rexach et al. | Recent developments in drug eluting devices with tailored interfacial properties | |
| Rivero et al. | Nanofibrous scaffolds for skin tissue engineering and wound healing applications | |
| CN106890368A (en) | For the ureter bracket and preparation method of tumour targeted therapy | |
| Eryildiz | Fabrication of drug-loaded 3D-printed bone scaffolds with radial gradient porosity | |
| JP2008253707A (en) | Drug-eluting stent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170627 |
|
| WD01 | Invention patent application deemed withdrawn after publication |